Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Med., 29 August 2025

Sec. Hepatobiliary Diseases

Volume 12 - 2025 | https://doi.org/10.3389/fmed.2025.1682417

Correction: Meta-analysis of the efficiency and safety of neoadjuvant therapy with immune checkpoint inhibitors in resectable hepatocellular carcinoma

This article is a correction to:

  1. Meta-analysis of the efficiency and safety of neoadjuvant therapy with immune checkpoint inhibitors in resectable hepatocellular carcinoma

    1. Read original article
Frontiers Production Office Frontiers Production Office*
  • Frontiers Media SA, Lausanne, Switzerland

A Correction on
Meta-analysis of the efficiency and safety of neoadjuvant therapy with immune checkpoint inhibitors in resectable hepatocellular carcinoma

by Tuersun, A., Mohetaer, M., Hou, G., and Cheng, G. (2025). Front. Med. 11:1511511. doi: 10.3389/fmed.2024.1511511

Authors Yadikaer Yasen and Xin Zhao were erroneously included as authors in the published article. The correct author list reads:

Adili Tuersun1, Munire Mohetaer2, Guanxin Hou3 and Gang Cheng4

1School of Life Sciences and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, Liaoning, China

2School of Business Administration, Shenyang Pharmaceutical University, Shenyang, China

3Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang, China

4Department of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China

The Author Contributions Statement has been corrected to read:

Author contributions

AT: Formal analysis, Methodology, Software, Validation, Writing – original draft, Writing – review & editing. MM: Conceptualization, Supervision, Validation, Writing – review & editing. GH: Software, Validation, Writing – review & editing. GC: Formal analysis, Software, Writing – original draft, Writing – review & editing.

The original version of this article has been updated.

Keywords: neoadjuvant immunotherapy, hepatocellular carcinoma, meta-analysis, safety, efficiency

Citation: Frontiers Production Office (2025) Correction: Meta-analysis of the efficiency and safety of neoadjuvant therapy with immune checkpoint inhibitors in resectable hepatocellular carcinoma. Front. Med. 12:1682417. doi: 10.3389/fmed.2025.1682417

Received: 08 August 2025; Accepted: 08 August 2025;
Published: 29 August 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, cHJvZHVjdGlvbi5vZmZpY2VAZnJvbnRpZXJzaW4ub3Jn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.